Siteman Investment Program (SIP) Awardees

The Siteman Investment Program is designed to award pilot funding to faculty investigators to support pioneering cancer research and produce data to leverage external peer reviewed funding.

2016 Cycle 2
Award Start Date: January 1, 2017

Pre-R01 WUSM for $200,000 over 2 years
James Skeath, PhD
A genetic model of perineural invasion

Steven Teitelbaum, MD
Fatty liver promotes hepatic breast cancer metastasis

Zhongsheng You, PhD
Nonsense-mediated mRNA decay in DNA damage response

Multi-PI Pre-R01 for $400,000 over 2 years
Nima Mosammaparast, MD, PhD
RNA as a target of alkylation chemotherapy in cancer

Terence Myckatyn, MD
Optimizing Decision Making about Breast Reconstruction after Mastectomy: A Patient-Centered Approach

Jay Piccirillo, MD
Evaluating Cognitive Function and Functional Connectivity In Breast Cancer Survivors Who Received Chemotherapy

Pre-SPORE/PPG for $400,000 over 1 year
William Gillanders, MD
Siteman Cancer Center Breast Cancer SPORE

2016 Cycle 1
Award Start Date: July 1, 2016

Pre-R01 Award, $200,000 over two years
Jeffrey Bednarski, MD, PhD
DNA Damage Mediated Checkpoints in Early B Cell Development

Ron Bose, MD, PhD
Targeting HER2 activating mutations in Metastatic Breast Cancer

Christopher Maher, PhD
The role of onco-lncRNA-230 as an epigenetic regulator of colon cancer metastasis

Jieya Shao, PhD
Functional Regulation of DNA Damage Response by the Ubiquitin-Selective Protein Segregase VCP
Tanya Wildes, MD, MSCI
Optimizing fall-risk prediction in older adults with cancer

Sergey Korolev, PhD, Saint Louis University
Mechanism and inhibition of PALB2 and BRCA2 proteins

Multi-PI Pre-R01, $400,000 over two years
Kendall Blumer, PhD
Direct pharmacological targeting of Gq/11 in uveal melanoma

2015 Cycle 2
Award Start Date: January 1, 2016

Pre-R01 for $200,000 over two years
Albert Kim, MD, PhD
Regulation of glioblastoma stem-like cells by CDC20-Anaphase-Promoting Complex

Kian Lim, MD, PhD
Deactivating the Innate Immune Defense Mechanism of Pancreatic Cancer

Ryan Teague, PhD, St. Louis University
Exploring T cell diversity as a novel mechanism for cancer immunotherapy

Pre-R01 for $100,000 over one year
Joseph Ippolito, MD, PhD
Characterizing the Effects of Sexual Dimorphism on Glioma Metabolism

Pre-R01 for $68,640 over one year
Graham Colditz, MD, DrPH
Premenopausal plasma carotenoids and incident premalignant breast diseases

Multi-PI Pre-R01 for $400,000 over two years
Jeff Milbrandt, MD, PhD
Axonal maintenance for prevention of chemotherapy-induced peripheral neuropathy

Pre-PPG for $800,000 over two years
Greg Longmore, PhD
Tumor-Environment Communication Regulating Metastasis

Pre-SPORE for $400,000 over one year
William Gillanders, MD
Siteman Cancer Center Breast Cancer SPORE
Pre-R01 Award, $200,000 over two years
David DeNardo, PhD
Targeting Focal Adhesion Kinase to Render Pancreatic Cancer Responsive to Immunotherapy

Todd Fehniger, MD, PhD
Memory-like natural killer (NK) cells for cancer immunotherapy

Multi-PI Pre-R01, $400,000 over two years
Matthew Walter, MD
Role of Subclones and Mutations in the Progression of MDS to Leukemia
(Award returned due to private funding from a foundation)

Dale Dorsett, PhD, St. Louis University
DNA Replication, Nuclear Architecture and Genome Stability

Pre-SPORE, $800,000 over two years
Jason Mills, MD, PhD
Mechanisms of Gastrointestinal Adenocarcinoma Tumorigenesis